CDK4 and melanoma: However, in addition to these favorable effects, continuous co-treatment with BRAFi, MEKi and CDK4/6i potently depletes melanoma tumors of myeloid cells, including immune-potentiating subsets, such as chemokine-producing macrophages and cross-priming CD103+ DCs18.